---
document_datetime: 2023-09-21 18:53:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/torisel-epar-procedural-steps-taken-authorisation_en.pdf
document_name: torisel-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5430553
conversion_datetime: 2025-12-18 10:54:59.249954
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Wyeth  Europa  Ltd.  submitted  on  05  October  2006  an  application  for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for TORISEL,  which  was  designated  as  an  orphan  medicinal  product  EU/3/03/365  on  06  April  2006. TORISEL was designated as an orphan medicinal product in the following indication: treatment of renal cell carcinoma. The calculated prevalence of this condition was 35 per 100,000 EU population, at the time of the designation.

The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  complete and independent application.

The applicant applied for the following indication treatment of advanced renal cell carcinoma.

## Information relating to Orphan Market Exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No  847/2000,  the  application  contained  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products.

## Protocol Assistance

The  applicant  received  Protocol  Assistance  from  the  CHMP  on  16  September  2004.  The  Protocol Assistance pertained to quality and clinical aspects of the dossier.

## Licensing status

TORISEL has been given a Marketing Authorisation in United States of America, for the treatment of advanced renal cell carcinoma on 30 May, 2007.

A  new  application  was  filed  in  the  following  countries:  Canada,  Switzerland,  Australia,  Japan, South Africa, Turkey, Taiwan, Mexico and Brazil.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Harald Enzmann Co-Rapporteur: Barbara van Zwieten-Boot

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 05 October 2006.
- The Rapporteur's first Assessment Report was circulated to all  CHMP members on 16 January 2007.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 19 January 2007.
- The procedure started on 25 October 2006.
- During  the  meeting  on  20-22  February  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the applicant on 23 February 2007.
- The  applicant submitted the responses to the CHMP  consolidated  List of Questions on 11 May 2007.
- The  summary  report  of  the  GCP  inspection  carried  out  at  the  following  sites  Professor  Ingo Schmidt-Wolf  (Bonn,  Germany)  on  05-08  February  2007,  Professor  El ż bieta  Staros ł awska (Lublin, Poland) on 12-16 February 2007  and at sponsor site, Wyeth  Research  Division (Cambridge, MA, USA) on 13-16 March 2007 was issued on 25 May 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 26 June 2007.

<div style=\"page-break-after: always\"></div>

- The  CHMP  adopted  a  report  on  similarity  of  TORISEL  with  Sutent  and  Nexavar  on  date 18 July 2007 (Appendix 1).
- During the CHMP meeting on 17-19 July 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant.
- The  applicant  submitted  the  responses  to  the  CHMP  revised  list  of  outstanding  issues  on 23 August 2007.
- During the meeting on 18-20 September 2007, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to TORISEL on 20 September 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 19 September 2007.
- The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 19 November 2007.